Functional MRI of disease progression in Parkinson disease and atypical parkinsonian syndromes

Neurology

Volumn 87, Issue 7, 2016, Pages 709-717

  Burciu, Roxana G ^a   Chung, Jae Woo ^b   Shukla, Priyank ^c   Ofori, Edward ^a   Li, Hong ^d   McFarland, Nikolaus R ^e   Okun, Michael S ^a   Vaillancourt, David E ^a  

^a Department of Applied Physiology and Kinesiology ^*  (United States)

^b Departments of Neurology   (United States)

^c Departments of Neurosurgery   (United States)

^d University of Florida   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CEREBELLUM; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PARKINSONISM; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PURDUE PEGBOARD TEST; PUTAMEN; SHY DRAGER SYNDROME; SUPPLEMENTARY MOTOR AREA; AGED; FOLLOW UP; HAND; HAND STRENGTH; LONGITUDINAL STUDY; MIDDLE AGED; MOTOR ACTIVITY; MOTOR CORTEX; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

AGED; CEREBELLUM; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HAND; HAND STRENGTH; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOTOR ACTIVITY; MOTOR CORTEX; MULTIPLE SYSTEM ATROPHY; PARKINSON DISEASE; PUTAMEN; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84983085507     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002985     Document Type: Article

References (40)

1. Vest RS, Pike CJ. Gender, sex steroid hormones, and Alzheimers disease. Horm Behav 2013;63:301-307.
2. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: longterm effects of the Womens Health Initiative. Menopause 2012;19:616-621.
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. JAMA 2002;288: 321-333.
4. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Womens Health Initiative randomized controlled trial. JAMA 2004;291: 1701-1712.
5. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2008;CD003122.
6. Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-cognitive and affective study. PLoS Med 2015;12:e1001833.
7. Henderson VW, Popat RA. Effects of endogenous and exogenous estrogen exposures in midlife and late-life women on episodic memory and executive functions. Neuroscience 2011;191:129-138.
8. Sherwin BB. Estrogen therapy: is time of initiation critical for neuroprotection? Nat Rev Endocrinol 2009;5:620-627.
9. Maki PM. Critical window hypothesis of hormone therapy and cognition: A scientific update on clinical studies. Menopause 2013;20:695-709.
10. Hodis HN, Mack WJ, Shoupe D, et al. Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis. Menopause 2014;22:391-401.
11. Henderson VW, St. John JA, Hodis HN, et al. Cognition, mood, and physiological concentrations of sex hormones in the early and late postmenopause. Proc Natl Acad Sci USA 2013;110:20290-20295.
12. Henderson VW, St John JA, Hodis HN, et al. Long-Term soy isoflavone supplementation and cognition in women: A randomized, controlled trial. Neurology 2012;78:1841-1848.
13. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D. Am J Prev Med 1994;10: 77-84.
14. Sherwin BB, Tulandi T. "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996;81:2545-2549.
15. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 1992;17:485-495.
16. Woo J, Lau E, Ho SC, et al. Comparison of Pueraria lobata with hormone replacement therapy in treating the adverse health consequences of menopause. Menopause 2003;10:352-361.
17. Shaywitz SE, Naftolin F, Zelterman D, et al. Better oral reading and short-Term memory in midlife, postmenopausal women taking estrogen. Menopause 2003;10:420-426.
18. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: The Heart and Estrogen/progestin Replacement Study. Am J Med 2002;113:543-548.
19. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. Estrogen therapy and risk of cognitive decline: results from the Womens Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 2005;192:387-393.
20. Resnick SM, Maki PM, Rapp SR, et al. Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J Clin Endocrinol Metab 2006;91: 1802-1810.
21. Resnick SM, Espeland MA, An Y, et al. Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J Clin Endocrinol Metab 2009;94:4152-4161.
22. Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause 2007;14:572-579.
23. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-Analysis. JAMA 2001;285:1489-1499.
24. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988;13:345-357.
25. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: Womens Health Initiative Memory Study. JAMA 2004;291:2959-2968.
26. Greenspan SL, Resnick NM, Parker RA. The effect of hormone replacement on physical performance in communitydwelling elderly women. Am J Med 2005;118:1232-1239.
27. Rapp SR, Espeland MA, Shumaker SA, et al. The effect of estrogen with progestin treatment on global cognitive function in postmenopausal women: results from the Womens Health Initiative Memory Study. JAMA 2003;289:2663-2672.
28. Tierney MC, Oh P, Moineddin R, et al. A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. Psychoneuroendocrinology 2009;37:1065-1074.
29. Yaffe K, Vittinghoff E, Ensrud KE, et al. Effects of ultralow-dose transdermal estradiol on cognition and healthrelated quality of life. Arch Neurol 2006;63:945-950.
30. Espeland MA, Shumaker SA, Leng I, et al. Long-Term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173:1429-1436.
31. Barha CK, Galea LA. The hormone therapy, Premarin, impairs hippocampus-dependent spatial learning and memory and reduces activation of new granule neurons in response to memory in female rats. Neurobiol Aging 2013;34:986-1004.
32. Brinton RD, Thompson RF, Foy MR, et al. Progesterone receptors: form and function in brain. Front Neuroendocrinol 2008;29:313-339.
33. Lowry NC, Pardon LP, Yates MA, Juraska JM. Effects of long-Term treatment with 17 beta-estradiol and medroxyprogesterone acetate on water maze performance in middle aged female rats. Horm Behav 2010;58:200-207.
34. Sherwin BB, Grigorova M. Differential effects of estrogen and micronized progesterone or medroxyprogesterone acetate on cognition in postmenopausal women. Fertil Steril 2011;96:399-403.
35. Maki PM. Minireview: effects of different HT formulations on cognition. Endocrinology 2012;153:3564-3570.
36. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: A critical time. JAMA 2002;288: 2170-2172.
37. Daniel JM. Estrogens, estrogen receptors, and female cognitive aging: The impact of timing. Horm Behav 2013;63: 231-237.
38. Smith CC, Vedder LC, Nelson AR, Bredemann TM, McMahon LL. Duration of estrogen deprivation, not chronological age, prevents estrogens ability to enhance hippocampal synaptic physiology. Proc Natl Acad Sci USA 2010; 107:19543-19548.
39. Rocca WA, Bower JH, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ III. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69: 1074-1083.
40. Ryan J, Scali J, Carriere I, et al. Impact of a premature menopause on cognitive function in later life. BJOG 2014; 121:1729-1739.